Industry News

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced it has received health authority approval in Belgium to commence a Phase 2 trial for INOpulse, its patented and proprietary pulsatile..."/>
Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD
Danaher Corporation today announced results for the second quarter 2016. For the quarter ended July 1, 2016, net earnings from continuing operations were $656.7 million, or $0.94 per diluted share on a GAAP basis, which represents a 5% year-over-year decrease. The results for the second quarter include the operations of Fortive Corporation, which was spun-off to Danaher's shareholders on July 2, 2016.."/>
Danaher Reports Second Quarter 2016 Results
Canopy Growth Corporation is pleased to announce that its wholly owned subsidiary Tweed Inc., Canada's largest medical marijuana producer, has received necessary approvals in Canada and Germany to begin export of medical cannabis for sale to German patients. Working with MedCann GmbH Pharma and Nutraceuticals, a privately held pharmaceutical importer and manufacturer, the transfer marks an important milestone for the Company and the..."/>
Tweed: Coming to a German Pharmacy Near You - Canadian market leader announces approvals to have Tweed products available for sale to German patients this summer
BIOLASE, Inc., the global leader in dental lasers, announced today that the Company will host a conference call on Monday, August 1, 2016 at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter and six months ended June 30, 2016, and to answer questions. A press release disclosing the Company's financial results will be distributed at approximately 4:05 p.m. Eastern Time that same day. Phone Participation To listen to the conference..."/>
BIOLASE® to Host 2016 Second Quarter Financial Results Conference Call on August 1
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company held on July 22, 2016 were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 10, 2016 and are available on the ICON plc website. The final results of the voting are as follows:."/>
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ImmunoCellular Therapeutics, Ltd. today reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly diagnosed glioblastoma and the phase 1 trial of ICT-121 for recurrent glioblastoma. In the ICT-107 phase 3 registrational trial, as of July 21, 2016, 109 patients have been screened in the US and Canada, with plans to randomize qualifying patients once they have completed..."/>
ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs
Mckesson was vetted as a possible surrogate for the Democratic National Committee, according to internal party emails published by WikiLeaks. The activist website released on Friday nearly 20,000 emails from top officials in the committee. "Hey team, can we please vet DeRay Mckesson... to act as a surrogate for us at a young professional event possibly featuring the Chair?""/>
WikiLeaks emails reveal DeRay Mckesson was vetted as a potential DNC surrogate [The Baltimore Sun]
Organigram Holdings Inc. is pleased to report its financial results for the third quarter ending May 31st, 2016. All amounts are expressed in Canadian dollars unless stated otherwise. Highlights from the quarter include:. --27% growth in sales compared to the prior quarter-- Net revenue of $8.47 per gram sold-- EBITDA1 growth to $695,721 from $370,139 in the prior quarter--------------------------------------------------------------- Summary Quarterly Results--------------------------------------------------------------- Operating/Financial Metric Q3 2016 Q2 2016--------------------------------------------------------------- Revenue$..."/>
Organigram Delivers Strong Results Across All Metrics in Q3
Capio swings to profit in Q2 2016
Capio swings to profit in Q2 2016
Mazor Robotics Ltd., a pioneer and a leader in the field of surgical guidance systems, today announced that it will report financial results for the second quarter ended June 30, 2016, before the U.S. markets open on Tuesday, August 2, 2016.. The company will host a conference call to discuss these results on Tuesday, August 2, 2016, at 8:30 AM ET. Investors within the United States interested in participating are invited to call 877-269-7756. Participants in..."/>
Mazor Robotics to Report Second Quarter Financial Results on August 2, 2016
AbbVie, a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for the use of 12 weeks of VIEKIRAX ® with ribavirin in genotype 4 chronic hepatitis C virus infected adult patients with compensated cirrhosis. VIEKIRAX with RBV is currently approved in the European Union for GT4 patients with compensated..."/>
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
ITC Ltd has appointed Sanjiv Puri, a wholetime director of the company, as chief operating officer with immediate effect, the company said in a filing to the Bombay Stock Exchange. On 6 December, Puri took over as executive director from 6 December, replacing P.V. Before that, Puri was the president of ITC's packaged goods business that accounts for about 80% of ITC's business."/>
Sanjiv Puri appointed COO of ITC; likely to replace Deveshwar [Mint, New Delhi]
Glenmark Pharmaceuticals Ltd on Monday said the US Food and Drug Administration has granted it final approval to launch an ointment for specific skin conditions in the US. The topical steroid, triamcinolone acetonide ointment, 0.5%, marketed by US-based Perrigo Co., is used to treat skin conditions such as eczema and psoriasis. It had sales of around 4.4 million dollars for the 12- month period ending May, Glenmark said, quoting US-based healthcare..."/>
BRIEF: Glenmark gets USFDA nod to launch ointment to treat eczema in US [Mint, New Delhi]
Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call at 10:30am Australian Eastern Daylight Time on Tuesday, July 26. The Company will discuss results from its Phase 1 dose escalation study of drug candidate OPT-302 in patients with wet age-related macular degeneration. To access the live webcast, please visit the Presentations page of the Opthea website at..."/>
Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302
Merrimack Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for ONIVYDE ®, also known as "nal-IRI", in combination with fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed after gemcitabine-based therapy. The CHMP positive opinion for ONIVYDE will now be..."/>
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
Shire plc today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the marketing authorization for the..."/>
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Tobira Therapeutics, Inc. today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Monday, July 25 to discuss Phase 2 b results for cenicriviroc in patients with non-alcoholic steatohepatitis and liver fibrosis. A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 859-2056 for domestic..."/>
Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of“ fibrosis” which includes a broad range of fibrosis/ fibrotic disease in different organs due to different causes.. Once issued, the patent..."/>
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials574 Articles
Consumer Discretionary521 Articles
Information Technology493 Articles
Industrials393 Articles
Health Care310 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.